Lyka Labs Limited (LYKALABS) AI Stock Analysis

• Market Cap: ₹2.86B
• Dividend Yield: N/A
• Average Volume (3M): 3.02K
• Price to Earnings (P/E): 139.1
• Beta (1Y): 1.14
• Revenue Growth: 4.04%
• EPS Growth: -35.02%
• Country: IN
• Employees: 423
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.94
• Shares Outstanding: 35,690,000
• 10 Day Avg. Volume: 1,252
• 30 Day Avg. Volume: 3,017
• PEG Ratio: -0.12
• Price to Book (P/B): 3.58
• Price to Sales (P/S): 2.64
• P/FCF Ratio: -26.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: ₹86.00 ▼(-8.90% Downside)

Lyka Labs Limited's overall stock score is primarily influenced by its strong revenue growth and operational efficiency improvements. However, the high liabilities, negative free cash flow, and bearish technical indicators significantly impact the score. The high P/E ratio further suggests overvaluation, contributing to a cautious outlook.

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding market presence and successful product adoption, supporting long-term business sustainability.

Operational Efficiency

Improved operational efficiency suggests effective cost management, enhancing profitability and competitive positioning in the market.

Equity Position

A stronger equity position reduces financial risk and provides a buffer for future investments and growth opportunities.

Negative Factors

High Liabilities

High liabilities can strain financial resources, limiting the company's ability to invest in growth and respond to market changes.

Negative Free Cash Flow

Negative free cash flow indicates challenges in funding operations and investments, potentially hindering future growth and innovation.

Cash Generation Challenges

Low cash generation from operations can limit flexibility in managing expenses and investing in new opportunities, affecting long-term growth.

Lyka Labs Limited Business Overview & Revenue Model

Company Description

Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. The company offers its products in various formulations, including injections, creams, ointments, gels, and lotions. It also exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.

How the Company Makes Money

Lyka Labs generates revenue through multiple streams including the direct sale of its health and wellness products via online platforms and retail partnerships. The company has established a subscription model that allows customers to receive regular shipments of their products, providing a stable and recurring income. Additionally, Lyka Labs may engage in partnerships with health professionals and wellness influencers to promote its offerings, further driving sales through collaborative marketing efforts. The company's focus on research and development also positions it to explore licensing opportunities for its proprietary formulations, potentially contributing to its earnings.

Lyka Labs Limited Financial Statement Overview

Summary

Lyka Labs Limited exhibits strong revenue growth and improved operational efficiency, as seen in increasing EBIT and EBITDA margins. The balance sheet shows a stronger equity position, but high liabilities and negative free cash flow pose financial risks.

Income Statement

Lyka Labs Limited has shown strong revenue growth, with a significant increase in Total Revenue from the previous years. The Gross Profit Margin is robust, indicating effective cost management. However, the Net Profit Margin has fluctuated, suggesting varying profitability levels. The EBIT and EBITDA margins have improved, reflecting enhanced operational efficiency over time.

Balance Sheet

The company has improved its financial position with increasing Stockholders' Equity, which has strengthened the Equity Ratio. The Debt-to-Equity Ratio has decreased, indicating reduced leverage. However, the overall liabilities remain high, posing potential financial risks. Return on Equity has improved due to better profitability in recent periods.

Cash Flow

Operating Cash Flow has been relatively stable but remains low compared to Net Income, indicating less cash generation from operations. Free Cash Flow has been negative, primarily due to high capital expenditures. The Free Cash Flow to Net Income ratio highlights challenges in converting profits into free cash flow, which could affect future investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.42B	1.41B	1.05B	916.90M	1.84B	671.07M
Gross Profit	853.99M	851.35M	599.41M	152.84M	1.30B	289.23M
EBITDA	204.94M	201.67M	167.59M	128.47M	1.01B	201.17M
Net Income	75.09M	80.12M	-24.89M	-132.12M	390.00M	-115.55M
Balance Sheet
Total Assets	0.00	1.76B	1.57B	1.52B	1.86B	1.90B
Cash, Cash Equivalents and Short-Term Investments	18.36M	13.63M	62.91M	119.39M	170.59M	76.30M
Total Debt	0.00	391.84M	586.50M	751.02M	1.30B	1.63B
Total Liabilities	-1.04B	726.24M	884.59M	1.06B	1.72B	2.15B
Stockholders Equity	1.04B	1.04B	681.54M	454.41M	133.38M	-257.97M
Cash Flow
Free Cash Flow	0.00	-137.55M	-74.58M	7.67M	717.33M	75.44M
Operating Cash Flow	0.00	18.99M	17.73M	89.53M	792.46M	88.11M
Investing Cash Flow	0.00	-117.96M	-94.88M	73.50M	-61.72M	-1.61M
Financing Cash Flow	0.00	52.92M	19.53M	-216.43M	-631.77M	-117.98M

Lyka Labs Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 94.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LYKALABS, the sentiment is Neutral. The current price of 94.4 is above the 20-day moving average (MA) of 77.39, above the 50-day MA of 82.14, and below the 200-day MA of 100.75, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 51.54 is Neutral, neither overbought nor oversold. The STOCH value of 55.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:LYKALABS.

Lyka Labs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDICO	76 Outperform	₹3.98B	35.10	―	―	21.55%	47.80%
SMSLIFE	69 Neutral	₹3.83B	20.49	―	0.12%	1.36%	-14.54%
ZIMLAB	63 Neutral	₹3.33B	50.60	―	―	-5.82%	-59.22%
NURECA	57 Neutral	₹2.83B	68.86	―	―	43.30%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LYKALABS	51 Neutral	₹2.86B	139.15	―	―	4.04%	-35.02%
BROOKS	45 Neutral	₹2.19B	15.97	―	―	18.67%	―

Lyka Labs Limited Corporate Events

Lyka Labs Confirms SEBI Dematerialisation Compliance for December Quarter

Lyka Labs Limited has reported that its registrar and share transfer agent, MUFG Intime India Private Limited, has issued a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31 December 2025. The certificate confirms that all securities received for dematerialisation during the quarter were duly processed, either accepted or rejected, listed on the appropriate stock exchanges, and that corresponding physical certificates were mutilated, cancelled, and replaced with depository records within prescribed timelines, underscoring the company’s adherence to regulatory requirements in handling its share capital.